CYP3A5 and myopathy: Non–statin-specific analysis showed an OR of 2.14 for subjects with CYP3A5*3 CC genotype in developing myopathy (p = 0.04). No significant effects observed in statin-specific analysis for both atorvastatin and rosuvastatin.